Ring Therapeutics is a biotechnology research company based in Cambridge, Massachusetts. Founded in 2017 by Flagship Pioneering, Ring is powering a new era of gene therapy by harnessing the unique biology of commensal anelloviruses. Their research aims to develop anellovirus-based therapies with tissue and cellular tropism, payload versatility, potency, and redosability.

Ring Therapeutics

Flagship Pioneering

Invus

Partners Investment

T. Rowe Price

UPMC Enterprises

Altitude Life Science Ventures

CJ Investment

Alexandria Venture Investments

Kyowa Kirin

#ICYMI we presented our first NHP data on our #Anellovectors and #AnelloBricks platform at #ESGCT2023. We’re dedicated to revolutionizing the gene therapy and nucleic acid medicine space. Catch up on the data presented here: https://brnw.ch/21wEiKw

Last week, our team took a break from the lab bench and headed out on a city-wide scavenger hunt for a chance to explore our new neighborhood in East Cambridge. Check out these selfies and sites from the competition & congrats to our winners Ashley Tang , Daniel Elliott MBA, SHRM-SCP, Gowtham Akash Jayakumar, Jake Matte, Kavya Atluri, Patricio Jeraldo, and Laurindo Fonseca for taking home the prize during this exciting team bonding activity!

We’ve landed in Brussels for #ESGCT2023! Come stop by and check out our posters showcasing the first NHP transduction data for our #Anellovectors and #AnelloBricks platform. If you can't make it, check out poster details here: https://brnw.ch/21wDRy3

This week, we are presenting new data at the 30th Annual European Society of Gene and Cell Therapy (ESGCT) Conference! Come check out our posters where Geoffrey Parsons will highlight the first NHP transduction data for #Anellovectors and our unique manufacturing approach with #AnelloBricks. Read more about our data here:  https://lnkd.in/eTzKS8td #ESGCT2023

Our #CEO Dr. Tuyen Ong was recently featured in a Genetic Engineering & Biotechnology News article discussing how anelloviruses can address current challenges in genetic medicine and the potential of AnelloVectors from our #Anellogy platform. Read more: https://brnw.ch/21wDorc

At Ring, we're translating the unique biology of commensal anelloviruses into AnelloVectors with our #Anellogy platform.  Learn more about how we're transforming these commensal viruses into life-saving therapies: https://brnw.ch/21wDcIe

We are incredibly proud to be part of Flagship Pioneering as we take bold leaps to tackle challenges in genetic medicine. At Ring, we’re committed to pushing the boundaries of what is possible with our #Anellogy platform. #FlagshipFounded

Today we announced two late-breaking presentations at the 30th Annual European Society of Gene and Cell Therapy (ESGCT) conference in Brussels! Come check out new data from our #Anellogy platform and learn about our unique approach to #genetherapy manufacturing. Read more about our presentation details here: https://brnw.ch/21wCWC7 #ESGCT2023

This summer, we transitioned to a new space to support the growth of our team! This space was meticulously designed to inspire brilliance & collaboration so we can continue pushing boundaries in genetic medicine with our #Anellogy platform. Join us: https://brnw.ch/21wCQrd

#TBT Our CEO Dr. Tuyen Ong chatted with Jonathan Grinstein from Genetic Engineering & Biotechnology News about addressing safety in gene editing and the importance of derisking novel approaches. Click here to read more:  https://fal.cn/3AqY4

msh id	COM:RINGTX
symbol	-
name	Ring Therapeutics
homepage url	https://ringtx.com
country	US
sector	Healthcare
industry	Biotechnology Research
market	PRIVATE
employee count	120
crunchbase url	https://www.crunchbase.com/organization/ring-therapeutics
linkedin url	https://www.linkedin.com/company/ring-therapeutics
founders	-

market cap	291.46M
enterprise value	-
stage	-
raised capital	-
valuation	-

monthly webtraffic	-
monthly webtraffic growth	-
growth score 14	46.8
growth score 28	16.59
growth score 90	51.14
growth score 365	28.13

revenue ltm	-
gross profit ltm	-
ebitda ltm	-
net income ltm	-
revenue ntm	-
gross profit ntm	-
ebitda ntm	-
net income ntm	-

growth cost and expenses	-
growth cost of revenue	-
growth depreciation and amortization	-
growth ebitda	-
growth ebitda ratio	-
growth eps	-
growth eps diluted	-
growth general and administrative expenses	-
growth gross profit	-
growth gross profit ratio	-

COM:RINGTX

Ring Therapeutics

Company Information

Market Metrics

Web & Growth Metrics

LTM & NTM Metrics

Growth & Performance Metrics

Operating Metrics

Balance Sheet Metrics

Financial Metrics (2022-2026)

cost and expenses	-
cost of revenue	-
depreciation and amortization	-
ebitda	-
ebitda ratio	-
eps	-
eps diluted	-
operating expenses	-
operating income	-
operating income ratio	-

accounts receivables	-
capital expenditure	-
cash at beginning of period	-
cash at end of period	-
inventory	-
working capital ttm	-

	2022	2023	2024	2025	2026
Revenue Metrics
Revenue	-	-	-	-	-
Revenue Growth	-	-	-	-	-
Revenue Multiple	-	-	-	-	-
Profit Metrics
Gross Profit	-	-	-	-	-
Gross Profit Growth	-	-	-	-	-
Gross Profit Multiple	-	-	-	-	-
EBITDA Metrics
EBITDA	-	-	-	-	-
EBITDA Growth	-	-	-	-	-
EBITDA Multiple	-	-	-	-	-
Net Income Metrics
Net Income	-	-	-	-	-
Net Income Growth	-	-	-	-	-
Net Income Multiple	-	-	-	-	-